BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999.
All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about May 16, 2025, subject to customary closing conditions.
Aura intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance its clinical programs in early-stage choroidal melanoma, metastases to the choroid, …
Full story available on Benzinga.com
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999.
All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about May 16, 2025, subject to customary closing conditions.
Aura intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance its clinical programs in early-stage choroidal melanoma, metastases to the choroid, …
Full story available on Benzinga.com
BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (NASDAQ:AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 11,735,565 shares of its common stock and accompanying warrants to purchase an aggregate of 2,933,891 shares of common stock and (ii) to certain investors, pre-funded warrants to purchase an aggregate of up to 3,571,435 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant, and accompanying warrants to purchase up to 892,858 shares of its common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase 0.25 of a share of common stock issued for each share of common stock or pre-funded warrant sold. The accompanying common stock warrant has an exercise price of $4.90 per share, is immediately exercisable from the date of issuance and will expire five years from the date of issuance. The combined offering price of each share of common stock and accompanying common stock warrant is $4.90. The combined offering price of each pre-funded warrant and accompanying common stock warrant is $4.89999.
All of the shares, pre-funded warrants and accompanying common stock warrants in the offering are being sold by Aura. The gross proceeds from the offering to Aura are expected to be $75.0 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about May 16, 2025, subject to customary closing conditions.
Aura intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance its clinical programs in early-stage choroidal melanoma, metastases to the choroid, …Full story available on Benzinga.com Read MoreAURA, News, IPOs, Press Releases News
